The following new policy was recently created:

Minimal Residual Disease Testing for Cancer – This new policy will be effective 1 de junio de 2023 and will include medical necessity criteria for CPT code 0364U for both Medicare Advantage plans and commercial products. Effective 1 de junio de 2023, for Medicare Advantage plans, CPT 0364U will change from being reviewed against criteria in the Genetic Testing Services policy to being reviewed against criteria in this policy. Also, effective 1 de junio de 2023, for commercial products, CPT code 0364U will be changed from not medically necessary to needing prior authorization following the medical necessity criteria identified in this new policy.